• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型自动化平台,用于使用骨扫描指数定量前列腺癌患者骨骼肿瘤受累程度。

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

机构信息

Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.

出版信息

Eur Urol. 2012 Jul;62(1):78-84. doi: 10.1016/j.eururo.2012.01.037. Epub 2012 Jan 27.

DOI:10.1016/j.eururo.2012.01.037
PMID:22306323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3402084/
Abstract

BACKGROUND

There is little consensus on a standard approach to analysing bone scan images. The Bone Scan Index (BSI) is predictive of survival in patients with progressive prostate cancer (PCa), but the popularity of this metric is hampered by the tedium of the manual calculation.

OBJECTIVE

Develop a fully automated method of quantifying the BSI and determining the clinical value of automated BSI measurements beyond conventional clinical and pathologic features.

DESIGN, SETTING, AND PARTICIPANTS: We conditioned a computer-assisted diagnosis system identifying metastatic lesions on a bone scan to automatically compute BSI measurements. A training group of 795 bone scans was used in the conditioning process. Independent validation of the method used bone scans obtained ≤3 mo from diagnosis of 384 PCa cases in two large population-based cohorts. An experienced analyser (blinded to case identity, prior BSI, and outcome) scored the BSI measurements twice. We measured prediction of outcome using pretreatment Gleason score, clinical stage, and prostate-specific antigen with models that also incorporated either manual or automated BSI measurements.

MEASUREMENTS

The agreement between methods was evaluated using Pearson's correlation coefficient. Discrimination between prognostic models was assessed using the concordance index (C-index).

RESULTS AND LIMITATIONS

Manual and automated BSI measurements were strongly correlated (ρ=0.80), correlated more closely (ρ=0.93) when excluding cases with BSI scores≥10 (1.8%), and were independently associated with PCa death (p<0.0001 for each) when added to the prediction model. Predictive accuracy of the base model (C-index: 0.768; 95% confidence interval [CI], 0.702-0.837) increased to 0.794 (95% CI, 0.727-0.860) by adding manual BSI scoring, and increased to 0.825 (95% CI, 0.754-0.881) by adding automated BSI scoring to the base model.

CONCLUSIONS

Automated BSI scoring, with its 100% reproducibility, reduces turnaround time, eliminates operator-dependent subjectivity, and provides important clinical information comparable to that of manual BSI scoring.

摘要

背景

目前对于骨扫描图像分析尚无标准方法。骨扫描指数(BSI)可预测进展性前列腺癌(PCa)患者的生存率,但由于手动计算繁琐,该指标的普及受到阻碍。

目的

开发一种全自动量化 BSI 的方法,并确定自动化 BSI 测量在常规临床和病理特征之外的临床价值。

设计、地点和参与者:我们对计算机辅助诊断系统进行了条件设置,使其能够在骨扫描上识别转移病灶,从而自动计算 BSI 测量值。在该方法的验证过程中,使用了一个包含 795 例骨扫描的训练组。该方法的独立验证使用了来自两个大型基于人群队列的 384 例 PCa 病例的≤3 个月诊断的骨扫描。一位经验丰富的分析人员(对病例身份、先前的 BSI 和结果均不知情)对 BSI 测量值进行了两次评分。我们使用预处理的 Gleason 评分、临床分期和前列腺特异性抗原来测量结局预测,同时纳入手动或自动化 BSI 测量值的模型。

测量

使用 Pearson 相关系数评估方法之间的一致性。使用一致性指数(C 指数)评估预后模型的区分度。

结果和局限性

手动和自动化 BSI 测量值高度相关(ρ=0.80),当排除 BSI 评分≥10(1.8%)的病例时相关性更紧密(ρ=0.93),并且在添加到预测模型后与 PCa 死亡独立相关(每种情况下 p<0.0001)。基础模型的预测准确性(C 指数:0.768;95%置信区间 [CI],0.702-0.837)通过添加手动 BSI 评分增加到 0.794(95% CI,0.727-0.860),通过将自动化 BSI 评分添加到基础模型增加到 0.825(95% CI,0.754-0.881)。

结论

自动化 BSI 评分具有 100%的可重复性,可缩短周转时间,消除操作员依赖性的主观性,并提供与手动 BSI 评分相当的重要临床信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/6e3e1597a113/nihms360159f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/9593635c69a6/nihms360159f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/626240a8a7cc/nihms360159f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/07e9adfc4309/nihms360159f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/6de14d9200dd/nihms360159f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/d43d082655b8/nihms360159f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/6e3e1597a113/nihms360159f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/9593635c69a6/nihms360159f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/626240a8a7cc/nihms360159f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/07e9adfc4309/nihms360159f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/6de14d9200dd/nihms360159f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/d43d082655b8/nihms360159f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/3402084/6e3e1597a113/nihms360159f6.jpg

相似文献

1
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.一种新型自动化平台,用于使用骨扫描指数定量前列腺癌患者骨骼肿瘤受累程度。
Eur Urol. 2012 Jul;62(1):78-84. doi: 10.1016/j.eururo.2012.01.037. Epub 2012 Jan 27.
2
Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.自动化骨扫描指数的分析验证:作为一种成像生物标志物,用于标准化转移性前列腺癌患者骨扫描的定量变化。
J Nucl Med. 2016 Jan;57(1):41-5. doi: 10.2967/jnumed.115.160085. Epub 2015 Aug 27.
3
Assessment of bone scans in advanced prostate carcinoma using fully automated and semi-automated bone scan index methods.应用全自动和半自动骨扫描指数方法评估晚期前列腺癌的骨扫描。
Ann Nucl Med. 2012 Aug;26(7):586-93. doi: 10.1007/s12149-012-0617-0. Epub 2012 Jun 29.
4
Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.骨扫描指数可预测转移性激素敏感性前列腺癌患者的预后。
BJU Int. 2016 May;117(5):748-53. doi: 10.1111/bju.13160. Epub 2015 Jun 13.
5
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.一种用于测量前列腺癌骨转移累及情况的新参数:骨扫描指数。
Clin Cancer Res. 1998 Jul;4(7):1765-72.
6
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.雄激素非依赖性前列腺癌患者骨转移灶范围的预后意义
J Clin Oncol. 1999 Mar;17(3):948-57. doi: 10.1200/JCO.1999.17.3.948.
7
Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.使用计算机辅助诊断系统对初治激素敏感性前列腺癌骨转移患者进行骨扫描时骨扫描指数的预后价值。
BMC Cancer. 2016 Feb 19;16:128. doi: 10.1186/s12885-016-2176-6.
8
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
9
A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer.一项评估转移性前列腺癌患者骨扫描用于定量评估的个体内重复性的前瞻性研究。
BMC Med Imaging. 2018 May 4;18(1):8. doi: 10.1186/s12880-018-0257-5.
10
Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.衡量不可衡量的指标:自动化骨扫描指数作为前列腺癌临床试验的定量终点。
Prostate Cancer Prostatic Dis. 2019 Dec;22(4):522-530. doi: 10.1038/s41391-019-0151-4. Epub 2019 Apr 29.

引用本文的文献

1
Novel Bone Scan Features for Predicting Prognosis in Men With Bone Metastatic Prostate Cancer: A Retrospective Study.预测骨转移前列腺癌男性患者预后的新型骨扫描特征:一项回顾性研究。
J Korean Med Sci. 2025 Aug 25;40(33):e206. doi: 10.3346/jkms.2025.40.e206.
2
ΔBSIJ: a quantitative marker for early detection of medication-related osteonecrosis of the jaw in patients with prostate cancer receiving bone-modifying agents.ΔBSIJ:一种用于早期检测接受骨改良剂治疗的前列腺癌患者颌骨药物相关性骨坏死的定量标志物。
Ann Nucl Med. 2025 Jul 3. doi: 10.1007/s12149-025-02078-9.
3
Comparison of the diagnostic accuracy of VSBONE BSI versions for detecting bone metastases in breast and prostate carcinoma patients using conventional and CZT detector gamma cameras.

本文引用的文献

1
Radionuclide based imaging of prostate cancer.放射性核素前列腺癌成像。
Curr Top Med Chem. 2010;10(16):1600-16. doi: 10.2174/156802610793176774.
2
Prostate kallikrein markers in diagnosis, risk stratification and prognosis.前列腺激肽释放酶标志物在诊断、风险分层和预后中的作用。
Nat Rev Urol. 2009 Jul;6(7):384-91. doi: 10.1038/nrurol.2009.123.
3
Computer-assisted interpretation of planar whole-body bone scans.平面全身骨扫描的计算机辅助解读。
使用传统伽马相机和CZT探测器伽马相机比较VSBONE BSI各版本在检测乳腺癌和前列腺癌患者骨转移方面的诊断准确性。
Ann Nucl Med. 2025 May;39(5):466-475. doi: 10.1007/s12149-025-02020-z. Epub 2025 Feb 14.
4
Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer.在接受六周期镭-223治疗的转移性去势抵抗性前列腺癌患者中,基线淋巴细胞功能可能是肿瘤负荷的新预测指标。
Cancers (Basel). 2024 Feb 22;16(5):886. doi: 10.3390/cancers16050886.
5
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.镭-223 治疗转移性去势抵抗性前列腺癌的循环和影像学生物标志物。
JCO Precis Oncol. 2024 Feb;8:e2300230. doi: 10.1200/PO.23.00230.
6
Bone Metastases Lesion Segmentation on Breast Cancer Bone Scan Images with Negative Sample Training.基于负样本训练的乳腺癌骨扫描图像骨转移病灶分割
Diagnostics (Basel). 2023 Sep 25;13(19):3042. doi: 10.3390/diagnostics13193042.
7
Skeleton Segmentation on Bone Scintigraphy for BSI Computation.用于骨闪烁成像骨闪烁指数(BSI)计算的骨骼分割
Diagnostics (Basel). 2023 Jul 6;13(13):2302. doi: 10.3390/diagnostics13132302.
8
Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial.在转移性去势抵抗性前列腺癌患者中使用自动骨扫描指数评估镭-223的治疗反应:来自J-RAP-BSI试验患者的数据。
Cancers (Basel). 2023 May 16;15(10):2784. doi: 10.3390/cancers15102784.
9
The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study.DASciS软件用于计算骨转移瘤负荷作为223RaCl2治疗的转移性去势抵抗性前列腺癌的重要预后工具:一项意大利多中心研究
Biomedicines. 2023 Apr 5;11(4):1103. doi: 10.3390/biomedicines11041103.
10
A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes.基于 PSMA PET 衍生的器官特异性肿瘤体积的前列腺癌预后风险评分。
Radiology. 2023 May;307(4):e222010. doi: 10.1148/radiol.222010. Epub 2023 Apr 18.
J Nucl Med. 2008 Dec;49(12):1958-65. doi: 10.2967/jnumed.108.055061. Epub 2008 Nov 7.
4
Quality of planar whole-body bone scan interpretations--a nationwide survey.平面全身骨扫描解读的质量——一项全国性调查。
Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1464-72. doi: 10.1007/s00259-008-0721-5. Epub 2008 Mar 29.
5
Stromal factors involved in prostate carcinoma metastasis to bone.参与前列腺癌骨转移的基质因素。
Cancer. 2003 Feb 1;97(3 Suppl):739-47. doi: 10.1002/cncr.11181.
6
The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants.马尔默饮食与癌症研究:参与者和非参与者的代表性、癌症发病率及死亡率
Eur J Cancer Prev. 2001 Dec;10(6):489-99. doi: 10.1097/00008469-200112000-00003.
7
The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma.前列腺癌患者骨转移的自然病史、骨骼并发症及治疗
Cancer. 2000 Jun 15;88(12 Suppl):2989-94. doi: 10.1002/1097-0142(20000615)88:12+<2989::aid-cncr14>3.3.co;2-h.
8
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.雄激素非依赖性前列腺癌患者骨转移灶范围的预后意义
J Clin Oncol. 1999 Mar;17(3):948-57. doi: 10.1200/JCO.1999.17.3.948.
9
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.一种用于测量前列腺癌骨转移累及情况的新参数:骨扫描指数。
Clin Cancer Res. 1998 Jul;4(7):1765-72.
10
Quantitative bone metastases analysis based on image segmentation.基于图像分割的定量骨转移分析。
J Nucl Med. 1997 Sep;38(9):1401-6.